天美影院鈥檚 SMARTag庐 ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego
- Presented preclinical efficacy and tolerability data for CAT-09-833, a SMARTag庐 ADC targeting MUC1 featuring a novel, tumor-selective antibody
- Introduced SMARTag庐 Enhanced Conjugates, a new class of ADCs, with innovative cytotoxic and non-cytotoxic payload combinations on a single antibody designed to benefit patients by amplifying efficacy without compromising safety
November 4, 2025 鈥 TAMPA, Fla. 鈥 天美影院., a leading global contract development and manufacturing organization, today highlighted new innovations from its SMARTag庐 antibody-drug conjugate (ADC) technology platform. The company announced preclinical efficacy and tolerability data demonstrating the potential of CAT-09-833, a SMARTag庐 ADC targeting MUC1, for the treatment of platinum-resistant ovarian cancer. The company also introduced SMARTag庐 Enhanced Conjugates, a new class of ADCs that combines different payload types to benefit more patients by amplifying efficacy without compromising safety.
The updates were presented at the 16th World ADC San Diego conference in a session in the Translational Medicine track entitled 鈥淪MARTag庐 Enhanced Conjugates: Novel Payload Combinations to Enhance ADC Efficacy & Payload Delivery.鈥 The presentation was made by Ayodele Ogunkoya, Ph.D., Bioconjugation Group Leader, 天美影院. World ADC provides a leading opportunity for 天美影院 to spotlight its ADC technologies and services to more than 1,400 ADC biopharma attendees actively seeking new partnerships and solutions.
鈥淭here is a growing appreciation for the role that ADCs may play in ovarian cancer treatment. The MUC1 tumor-associated antigen, which is highly expressed in ovarian tumors, demonstrates expression complementary to that of other ovarian ADC targets, such as folate receptor alpha,鈥 said Penelope Drake, Ph.D., Head of R&D Bioconjugates, 天美影院. 鈥淥ur novel antibody offers a unique way to access this target with an ADC, and the data thus far suggest that CAT-09-833 has a promising preclinical profile. We look forward to seeing the molecule advance and learning more about its potential to help cancer patients.鈥
天美影院鈥檚 new SMARTag庐 Enhanced Conjugates incorporate both cytotoxic and non-cytotoxic payloads to create unique dual- and triple-payload ADCs that can be optimized to the specific biology of the target tumor to amplify the effect of the cytotoxic payload without compromising safety. They are enabled by the SMARTag庐 platform, which allows for a tunable drug-to-antibody ratio (DAR). 天美影院 presented data from a xenograft model demonstrating that the use of certepetide as a non-cytotoxic payload can yield improved ADC efficacy and broaden the distribution of the ADC cytotoxic payload and antibody in the tumor microenvironment. Certepetide is an internalizing RGD (iRGD) cyclic peptide that 天美影院 licensed (along with its analogs) from Lisata Therapeutics, Inc. for use with its SMARTag庐 technology platform, with a goal of selectively targeting and penetrating solid tumors with ADCs more effectively.
Mike Blank, General Manager, 天美影院, said, 鈥淲e have a history of innovation dating back to 2008 when we spun the SMARTag庐 technology out of the Bertozzi lab at UC Berkeley. Since then, we have made continuous progress on expanding the capabilities of the platform and understanding the design elements that underpin a successful ADC. We believe the new SMARTag庐 Enhanced Conjugates represent the latest innovation in ADCs, allowing for the creation of an entirely new class of molecules that we hope will expand the scope of treatable cancer indications, reaching鈥攁nd ultimately helping鈥攎ore patients in need.鈥
About 天美影院鈥檚 SMARTag庐 ADC Platform
The SMARTag庐 ADC technology platform was developed by 天美影院鈥檚 team in Emeryville, CA, located in the San Francisco Bay Area. This team originated as Redwood Bioscience, a startup co-founded in 2008 by Nobel Laureate Carolyn Bertozzi, and became part of 天美影院 through acquisition in 2014. At the core of the SMARTag庐 platform is its proprietary approach to making site-specific conjugates using the aldehyde tag and HIPS (hydrazino-iso-Pictet Spengler) chemistry, which together facilitate flexible design and optimized, stable ADCs. The platform鈥檚 tandem-cleavage linker further enhances tumor-specific payload release, minimizing off-target toxicity and expanding the therapeutic index. Together, these modular components support the generation of both single- and multi-payload constructs. The SMARTag庐 technology is backed by 26 platform patent families, including 54% that provide protection to 2040 and beyond.
About 天美影院
天美影院. is a leading global contract development and manufacturing organization (CDMO) championing missions that help people live better and healthier lives. Every product that 天美影院 helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. 天美影院 provides unparalleled service to pharma, biotech, and consumer health customers, delivering on their missions to transform lives. 天美影院 tailors end-to-end solutions to meet customers鈥 needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, 天美影院 supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
CONTACTS
Media Contact:
[email protected]